최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기藥劑學會誌 = Journal of Korean pharmaceutical sciences, v.40 no.2, 2010년, pp.91 - 100
최유리 (숙명여자대학교 약학대학) , 오승열 (숙명여자대학교 약학대학)
The objective of this work is to study transdermal delivery of donepezil hydrochloride (DH) using iontophoresis and to evaluate various factors which affect the transdermal transport. After the flux study using 4 kinds of hydrogel, hydrogel containing 8% poly(ethylene oxide) (PEO) was chosen as the ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Alzheimer’s disease란 무엇인가? | Alzheimer’s disease는 혈관성 치매, 특정 뇌질환, 전신성 질환의 원인으로 구분되는 치매의 증상 중 가장 대표적인 것으로 50% 이상을 차지하는 질환이다.4) 이 질병은 1906년 뇌신경질환으로 사망한 환자의 뇌조직 변화를 관찰해 특징적인 병리소견을 발견한 Alois Alzheimer의 이름을 따서 붙인 병명이다. | |
Alzheimer’s disease는 어떠한 증상이 나타나는가? | 뇌세포가 파괴되는 과정에서 Acetylcholine이라는 신경전달물질이 감소하여 증세가 나타나는데, 아직까지 정확한 발생원인과 치료대책은 밝혀지지 않았다.5-7) 기억력 손상, 인지력 장애, 행동 장애 등의 증상이 나타나며, Alzheimer’s disease의 치료는 증상의 진행을 늦추고 있을 뿐, 근본적인 원인치료는 아직 개발되지 않았다. 현재 사용되고 있는 약물로는 AchE (Acetylcholine-sterase) 억제제인 Cognex® (Tacrine), Aricept® (Donepezil), Exelon® (Rivastigmine) 등과 NMDA 수용체길항제인 Namenda® (Memantine) 등이 있다. | |
Alzheimer’s disease의 병명은 어떻게 이름 짓게 되었는가? | Alzheimer’s disease는 혈관성 치매, 특정 뇌질환, 전신성 질환의 원인으로 구분되는 치매의 증상 중 가장 대표적인 것으로 50% 이상을 차지하는 질환이다.4) 이 질병은 1906년 뇌신경질환으로 사망한 환자의 뇌조직 변화를 관찰해 특징적인 병리소견을 발견한 Alois Alzheimer의 이름을 따서 붙인 병명이다. 이것은 뇌신경세포 사이에 베타아밀로이드 단백질이 축적되고 neuron 내에 tangle이 생겨 비정상적인 단백질이 축적되어 뇌세포의 파괴를 일으킨다. |
J.H. Jhoo, K.W. Kim, Y. Huh, S.B. Lee, J.H. Park, J.J. Lee, E.A. Choi, C. Han, I.H. Choo, J.C. Youn, D.Y. Lee and J.I. Woo. Prevalence of dementia and its subtypes in an elderly urban Korean population: results from the Korean Longitudinal Study on Health And Aging (KLoSHA), Dement. Geriatr. Cogn. Disord., 26(3), 270-276 (2008).
R. Brookmeyer, E. Johnson, K. Ziegler-Graham and H.M. Arrighi, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement., 3(3), 186-191 (2007).
E. England, Improving the management of dementia. BMJ, 332(7543), 681-682 (2006).
H.W. Querfurth and F.M. LaFerla, Alzheimer's Disease, N. Engl. J. Med., 362, 329-344 (2010).
P.T. Francis, A.M. Palmer, M. Snape and G.K. Wilcock, The cholinergic hypothesis of Alzheimer's disease: a review of progress, J. Neurol. Neurosurg. Psychiatry., 66(2), 137-147 (1999).
S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher and K.H. Ashe, A specific amyloid-beta protein assembly in the brain impairs memory, Nature, 440(7082), 352-357 (2006).
C. Zhao, W. Deng and F.H. Gage. Mechanisms and functional implications of adult neurogenesis, Cell, 132(4), 645-660 (2008).
R.S. Upasani and A.K. Banga, Response surface methodology to investigate the iontophoretic delivery of tacrine hydrochloride. Pharm. Res., 21(112), 2293-2299 (2004).
T. Kankkunen, R. Sulkava, M. Vuorio, K. Kontturi and J. Hirvonen, Transdermal iontophoresis of tacrine in vivo, Pharm. Res., 19(5), 704-707 (2002).
N. Giladi, H. Shabtai, T. Gurevich, B. Benbunan, M. Anca and A.D. Korczyn, Rivastigmine (Exelon) for dementia in patients with Parkinson's disease, Acta. Neurol. Scand., 108(5), 368-373 (2003).
A.Z. Ables, Memantine (Namenda) for moderate to severe Alzheimer's disease, Am. Fam. Physician, 69(6), 1491-1492 (2004).
B. Winblad, J. Cummings, N. Andreasen, G. Grossberg, M. Onofrj, C. Sadowsky, S. Zechner, J. Nagel and R. Lane, A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's diseaserivastigmine patch versus capsule, Int. J. Geriatr. Psychiatry, 22(5), 456-467 (2007).
D.P. Reiss, Physician's Desk Reference, 53th ed, Montvale : Medical Economics Company, 2364-2367 (1999).
M.L. Crismon, Pharmocokinetics and drug interaction of cholinesterase inhibitors administered in Alzheimer’s disease, Pharmacotherapy, 18(2Pt2), 47-54 (1988).
P.S. Kishnani, J.A. Sullivan, B.K. Walter, G.A. Spiridigliozzi, P.M. Doraiswamy and K.R. Krishnan, Cholinergic therapy for Down’s syndrome, Lancet, 353(9158), 1064-1065 (1999).
S.L. Rogers and L.T. Friedhoff, The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled study, Dementia, 7(6), 293-303 (1996).
H. Choi (Ed.), Transdermal dosage form, Shinil publication, 136-138 (1999).
Y.W. Chien and C.S. Lee, In Controlled Release Technology: Pharmaceutical Applications (Ed. P.I. Lee and W.R. Good), J. Am. Chem. Soc., Washington DC, chapter 21 (1987).
Y.N. Kalia, A. Naik, J. Garrison and R.H. Guy, Iontophoretic drug delivery, Adv. Drug Deliv. Rev., 56(5), 619-658 (2004).
J.Y. Fang, K.C. Sung, H.H. Lin and C.L. Fang, Transdermal iontophoretic delivery of diclofenac sodium from various polymer formulations: in vitro and in vivo studies, Int J Pharm., 178(1), 83-92 (1999).
B. Langer, New methods of drug delivery, Science, 249(4976), 1527-1533 (1990).
M.D. Blanco, O. Garca, R. Olmo, J.M. Teijon and I. Katime, Release of 5-fluorouracil from poly (acrylamide-comonopropyl itaconate) hydrogels, J. Chromatogr. B. Biomed. Appl., 680, 243-253 (1996).
F.E. Bailey Jr. and J.V. Koleske, poly (ethylene oxide), Academic Press, New York, U.S.A. (1976).
F.G. Hutchinson, Medical and pharmaceutical applications of water-soluble polymers : In Chemistry and Technology of water-soluble polymers, C.A. Finch (Ed.), Plenum Press, New York, U.S.A., 267-285 (1983).
N.B. Graham, Poly (ethylene oxide) and related hydrogels : In Hydrogels in Medicine and Pharmacy, Vol11, N.A. Peppas (Ed.), CRC Press, Boca Raton, U.S.A., 95-113 (1987).
S.A. Jung, H.S. Gwak, I.K. Chun and S.Y. Oh, Levodopa transport through skin using iontophoresis: the role of electroosmosis and electrorepulsion, J. Kor. Pharm. Sci., 38(1), 31-38 (2008).
J.E. Riviere and M.C. Heit, Electrically-assisted transdermal drug delivery, Pharm. Res., 14(6), 687-697 (1997).
O.D. Uitto and H.S. White, Electroosmotic pore transport in human skin, Pharm. Res., 20(4), 646-652 (2003).
V. Merino, A. Lopez, Y.N. Kalia and R.H. Guy, Electrorepulsion versus electroosmosis : effect of pH on the iontophoresis flux of 5-fluorouracil, Pharm. Res., 16(5), 758-761 (1999).
J. Hirvonen and R.H. Guy, Transdermal iontophoresis: modulation of electroosmosis by polypeptides, J. Control. Release, 50, 283-289 (1998).
S. Oh, Effect of formulation additives on the electroosmosis during iontophoresis, Abrtracts, The fifth asian international symposium on biomaterials, Biomaterial society of China, p. 308 (2006).
A. Kim, P.G. Green, G.Rao and R.H. Guy, Convective solvent flow across the skin during iontophoresis, Pharm. Res., 10(9), 1315-1320 (1993).
D. Marro, R.H. Guy and M.B. Delgado-Charro, Characterization of the iontophoretic permselectivity properties of human and pig skin, J. Control. Release., 70, 213-217 (2001).
R.H. Guy, Y.N. Kalia, M.B. Delgado-Charro, V. Merino, A. Lopez and D. Marro, Iontophoresis : electrorepulsion and electroosmosis, J. Control. Rel., 64, 129-132 (2000).
B.D. Bath, H.S. White and E.R. Scott, Visualization and analysis of electroosmotic in hairless mouse skin, Pharm. Res., 17(4), 471-475 (2000).
D. Marro, R.H. Guy, and M.B. Delgado-Charro, Characterization of the iontophoretic permselectivity properties of human and pig skin, J. Control. Release, 70, 213-217 (2001).
P.C. Kuo, Kinetics of transdermal permeation of oxycodone HCl and the enhancement by iontophoresis, M. Sc. thesis, Rutgers University, New Brunswick, N J.
J.C. Liu, Y. Sun, O. Siddiqui, Y.W. Chien, W. M. Shi and J. Li, Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin, Int. J. Pharma., 44, 197-204 (1988).
R.R. Burnette and T.M. Bagniefski, Influence of constant current iontophoresis on the impedance and passive Na+ permeability of excised mouse skin, J. Pharm. Sci., 77(6), 492-497 (1988).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.